EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial

Akihiro Ohba iD, Chigusa Morizane iD, Yasuyuki Kawamoto iD, Yoshito Komatsu iD, Makoto Ueno iD, Satoshi Kobayashi iD, Masafumi Ikeda iD, Mitsuhito Sasaki iD, Junji Furuse iD, Naohiro Okano iD, Nobuyoshi Hiraoka, Hiroshi Yoshida iD und 8 weitere

Journal of Clinical Oncology · 20.09.2024 · 42 (27) · 3207-3217

DOI: 10.1200/jco.23.02010 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.09.2024. Verfasst von Akihiro Ohba und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Biliary Tract Neoplasms. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Treatment options for patients with unresectable or recurrent biliary tract cancer (BTC) who progress on a gemcitabine-containing regimen are limited. In addition, the significance of anti–human epidermal growth factor receptor 2 (HER2) therapy in HER2-expressing BTC has not been sufficiently investigated. METHODS In this phase II trial, participants from five institutions in Japan were enrolled. Eligible patients had pathologically confirmed unresectable or recurrent BTC with centrally confirmed HER2-positive (immunohistochemistry [IHC]3+ or IHC2+ and in situ hybridization [ISH]+) or HER2-low (IHC2+ and ISH–, IHC1+, and IHC0 and ISH+) and were refractory or intolerant to a gemcitabine-containing regimen. The patients received 5.4 mg/kg trastuzumab deruxtecan (T-DXd) once every 3 weeks until disease progression or unacceptable toxicity. The primary end point was the confirmed objective response rate (ORR) in HER2-positive BTC by an independent central review (threshold ORR, 15%; expected ORR, 40%). RESULTS A total of 32 patients were enrolled and treated. Among these patients, 22 with HER2-positive disease comprised the primary efficacy population and had a confirmed ORR of 36.4% (90% CI, 19.6 to 56.1; P = .01), meeting the primary end point. Eight with HER2-low disease comprised the exploratory population and had a confirmed ORR of 12.5%. The most common ≥grade 3 treatment-related adverse events were anemia (53.1%) and neutropenia (31.3%). Eight patients (25.0%) had interstitial lung disease (ILD), including two grade 5 events. CONCLUSION T-DXd showed promising activity in patients with HER2-positive BTC and a signal of efficacy in patients with HER2-low BTC. Although the safety profile was generally manageable, ILD requires careful monitoring and early intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabErb-b2 Receptor Tyrosine KinasesBiliary Tract NeoplasmsHumansFemaleMaleAgedMiddle AgedCamptothecinAdultAntineoplastic Agents, ImmunologicalAged, 80 and overImmunoconjugates

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesCamptothecinAntineoplastic Agents, ImmunologicalImmunoconjugatesERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.
  • Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
  • Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, Yoshito Komatsu, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Mitsuhito Sasaki, Junji Furuse, Naohiro Okano, Hiroshi Yoshida, Aya Kuchiba, Ryo Sadachi, Kenichi Nakamura, Yoshiaki Nakamura, Wataru Okamoto, Takayuki Yoshino, Takuji Okusaka

Zitieren

APA

Ohba, A., Morizane, C., Kawamoto, Y., Komatsu, Y., Ueno, M., Kobayashi, S., Ikeda, M., Sasaki, M., Furuse, J., Okano, N., Hiraoka, N., Yoshida, H., Kuchiba, A., Sadachi, R., Nakamura, K., Matsui, N., Nakamura, Y., Okamoto, W., Yoshino, T., & Okusaka, T. (2024). Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. Journal of Clinical Oncology, 42(27), 3207-3217. https://doi.org/10.1200/jco.23.02010

Vancouver

Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, et al. Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. Journal of Clinical Oncology. 2024;42(27):3207-3217. doi:10.1200/jco.23.02010

BibTeX
@article{Ohba2024,
  author = {Ohba, Akihiro and Morizane, Chigusa and Kawamoto, Yasuyuki and Komatsu, Yoshito and Ueno, Makoto and Kobayashi, Satoshi and Ikeda, Masafumi and Sasaki, Mitsuhito and Furuse, Junji and Okano, Naohiro and Hiraoka, Nobuyoshi and Yoshida, Hiroshi and Kuchiba, Aya and Sadachi, Ryo and Nakamura, Kenichi and Matsui, Naoko and Nakamura, Yoshiaki and Okamoto, Wataru and Yoshino, Takayuki and Okusaka, Takuji},
  title = {Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {27},
  pages = {3207--3217},
  doi = {10.1200/jco.23.02010}
}
Kostenlos starten →